Interpretation of Enhanced Fecal and Urinary Plutonium Excretion Data under a 2-y Regular DTPA Treatment Started Months after Intake

Abstract In a worker who had internalized plutonium, most likely through inhalation of a somewhat soluble compound, an extensive diethylenetriaminepentaacetate (DTPA) treatment regimen was initiated several months after contamination. Numerous radiotoxicological analyses were performed in both fecal and urinary specimens collected, sometimes for three consecutive days after DTPA administration. Activity measurements showed the continued effectiveness of DTPA intravenous infusions in removing plutonium from tissues of retention even if the treatment regimen started very belatedly after contamination. In the present case, the activity excreted through urine within the first 24-h after a DTPA infusion contributed only about half of that activity excreted within the first three days (i.e., the cumulative activity of the first three 24-h urine collections). In addition, the careful study of the data revealed that DTPA-induced excretion of plutonium via fecal pathway significantly contributed to the overall decorporation. The intracellular chelation of plutonium may be responsible for this enhanced excretion of activity in feces as well as for the delayed and sustained increased clearance of activity in urine. The authors would suggest that the occupational physicians offer to individuals who internalized moderately soluble or soluble plutonium compounds undergo a long-term DTPA treatment, especially when it is not initiated promptly after intake. Under this scenario, measurements of plutonium in successive urine and fecal collections after treatment should be required to get a better estimate of the therapeutic benefit. Also, intracellular chelation and fecal route should be taken into account for better interpretation of radiotoxicological data and modeling of plutonium kinetics under delayed DTPA treatment.

[1]  G. Miller,et al.  Development of a New Chelation Model: Bioassay Data Interpretation and Dose Assessment after Plutonium Intake via Wound and Treatment with DTPA , 2020, Health physics.

[2]  D. Poudel,et al.  Chelation Modeling: The Use of Ad Hoc Models and Approaches to Overcome a Dose Assessment Challenge. , 2019, Health physics.

[3]  L. Miccoli,et al.  Comments on “Improved Modeling of Plutonium-DTPA Decorporation” (Radiat Res 2019; 191:201-10) , 2019, Radiation Research.

[4]  D. J. Strom,et al.  Response to the Letter to the Editor, ‘Comments on “Improved Modeling of Plutonium-DTPA Decorporation,” (Radiat Res 2019; 191:201-10) by Gremy and Miccoli’ , 2019, Radiation Research.

[5]  M. Avtandilashvili,et al.  Evaluating Plutonium Intake and Radiation Dose Following Extensive Chelation Treatment. , 2019, Health physics.

[6]  D. J. Strom,et al.  Validation of a system of models for plutonium decorporation therapy , 2019, Radiation and Environmental Biophysics.

[7]  B. Breustedt,et al.  USTUR Case 0846: Modeling Americium Biokinetics After Intensive Decorporation Therapy , 2018, Health physics.

[8]  D. J. Strom,et al.  Improved Modeling of Plutonium-DTPA Decorporation , 2018, Radiation Research.

[9]  L. Miccoli,et al.  Decorporation Approach after Rat Lung Contamination with Plutonium: Evaluation of the Key Parameters Influencing the Efficacy of a Protracted Chelation Treatment , 2017, Radiation Research.

[10]  L. Miccoli,et al.  Decorporation of Pu/Am Actinides by Chelation Therapy: New Arguments in Favor of an Intracellular Component of DTPA Action , 2016, Radiation Research.

[11]  R. Brey,et al.  Plutonium-DTPA Model Application with USTUR Case 0269 , 2016, Health physics.

[12]  D. Renault,et al.  Plutonium behavior after pulmonary administration according to solubility properties, and consequences on alveolar macrophage activation. , 2012, Journal of radiation research.

[13]  E. Fattal,et al.  Simplified Structure of a New Model to Describe Urinary Excretion of Plutonium after Systemic, Liver or Pulmonary Contamination of Rats Associated with Ca-DTPA Treatments , 2009, Radiation research.

[14]  E. H. Carbaugh,et al.  Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu. , 2007, Radiation protection dosimetry.

[15]  P. Bérard,et al.  Exposure to actinides: report on Ca-DTPA injections in CEA-AREVA centres , 2007 .

[16]  D. Taylor,et al.  Treatment of accidental intakes of plutonium and americium: guidance notes. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[17]  J. Delforge,et al.  Comparative tissue uptake and cellular deposition of three different plutonium chemical forms in rats , 2004, International journal of radiation biology.

[18]  P. Durbin,et al.  Competitive binding of Pu and Am with bone mineral and novel chelating agents. , 2003, Radiation protection dosimetry.

[19]  M. Bhattacharyya,et al.  Guidebook for the treatment of accidental internal radionuclide contamination of workers , 1992 .

[20]  H. Doerfel,et al.  Incorporation of 241Am: Effectiveness of Late DTPA Chelation Therapy , 1989 .

[21]  M. Bailey,et al.  The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection. , 1983, Health physics.

[22]  J. Hendry,et al.  Bone and Bone Seeking Radionuclides: Physiology, Dosimetry, and Effects , 1982 .

[23]  M. Bhattacharyya,et al.  Action of DTPA on hepatic plutonium. III. Evidence for a direct chelation mechanism for DTPA-induced excretion of monomeric plutonium into rat bile. , 1979, Radiation research.

[24]  W Stevens,et al.  The retention and distribution of 241Am and 65Zn, given as DTPA chelates in rats and of [14C]DTPA in rats and beagles. , 1978, Radiation research.

[25]  Smith Ja,et al.  A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy. , 1978 .

[26]  M. Bhattacharyya,et al.  Action of DTPA on hepatic plutonium I. Quantitation of the DTPA-induced biliary excretion of plutonium in the rat. , 1978, Radiation research.

[27]  B. Grube,et al.  The retention of plutonium in hepatocytes and sinusoidal lining cells isolated from rat liver. , 1978, Radiation research.

[28]  J. Smith,et al.  A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy. , 1978, Health physics.

[29]  J. Lynn,et al.  Assessment and management of a plutonium contaminated wound case. , 1974, Health physics.

[30]  Jr. John A. Wethington,et al.  Assessment of Radioactive Contamination in Man , 1973 .

[31]  G. Poda,et al.  Treatment and evaluation of a plutonium-238 nitrate contaminated puncture wound. A two-year case history. , 1972, Health physics.

[32]  K. Heid,et al.  Interpretation of human urinary excretion of plutonium for cases treated with DTPA. , 1972, Health physics.

[33]  J. E. Ballou,et al.  Biliary plutonium excretion in the rat. , 1972, Health physics.

[34]  J. Alderhout.  BIO-ASSAY RESULTS OF A CASE OF PLUTONIUM INHALATION. , 1972 .

[35]  D. Taylor,et al.  The binding of thorium(IV), plutonium(IV), americium(3) and curium(3) to the constituents of bovine cortical bone in vitro. , 1972, Radiation research.

[36]  J. Horm,et al.  Urinary excretion of 241Am under DTPA therapy. , 1971, Health physics.

[37]  D. Taylor,et al.  The binding of americium and plutonium to bone glycoproteins. , 1970, European journal of biochemistry.

[38]  W. J. Clarke,et al.  Effectiveness of DTPA in Removing Plutonium from the Pig.∗ , 1961 .

[39]  W. Norwood.  DTPA--effectiveness in removing internally deposited plutonium from humans. , 1960, Journal of occupational medicine. : official publication of the Industrial Medical Association.